We Must Win The Race For Global Biotech Innovation

According to the Information Technology and Innovation Foundation, China’s share of global biopharma companies increased from 5% to 16% between 2017 and 2024, while our share decreased from 47% to 39%. China’s share of global biotech venture capital surged from 4% to 19% from 2010 to 2020, while our share declined from 69% to 62%. China-headquartered companies’ share of global clinical trial starts jumped from 3% to 28% from 2013 to 2023, while our share dwindled from 37% to 29%. China’s most-cited biotech publications nearly quintupled from 139 to 671, while ours shrank by one-third from 218 to 145.